In terms of your expectations, I'm not sure how I can help you there. We've been clear about the fact that this is preliminary data. The interim data shows that there is a positive response in patients dosed so far. This patient population is facing a severely aggressive and life threatening disease, and currently have no therapies aside from debilitating surgery, chemotherapy and radiation. Our responder who had tried other treatments with no success, showed a positive response to ImmunoPulse – this could potentially eradicate his life threatening disease. Imagine you were suffering from such a disease with no hope after trying various therapies that didn't work, and to finally try a treatment that showed a 70% regression in tumors – would you find this positive?
The data was significant enough for our investigator, a respected doctor in his field, to submit it to SITC and it was significant enough for SITC to invite us to present a poster. In fact, this is the first time immunotherapy data is being even provided for this indication let alone the first human data for merkel cell for electroporation and the fact that we are indicating that there has been t-cell response in one or more of these patients.
I do think the trials will get better and more positive responses will occur. We are on the ground level of possibly something huge. Yes, it's early and this a long tedious process. The next trial will be a making or breaking point IMO The fact that they are even presenting in these trials is a positive indicator. Doctor's don't just submit any data to SITC without significance